Signs and symptoms of pancreatitis include pain in the upper abdomen, nausea and vomiting.[1] The pain often goes into the back and is usually severe.[1] In acute pancreatitis, a fever may occur; symptoms typically resolve in a few days.[1] In chronic pancreatitis, weight loss, fatty stool, and diarrhea may occur.[1][5] Complications may include infection, bleeding, diabetes mellitus, or problems with other organs.[1]
The two most common causes of acute pancreatitis are a gallstone blocking the common bile duct after the pancreatic duct has joined; and heavy alcohol use.[1] Other causes include direct trauma, certain medications, infections such as mumps, and tumors.[1] Chronic pancreatitis may develop as a result of acute pancreatitis.[1] It is most commonly due to many years of heavy alcohol use.[1]
Acute pancreatitis is usually treated with intravenous fluids, pain medication, and sometimes antibiotics.[1] Typically eating and drinking are disallowed, and a nasogastric tube is placed in the stomach.[1] A procedure known as an endoscopic retrograde cholangiopancreatography (ERCP) may be done to examine the distal common bile duct and remove a gallstone if present.[1] In those with gallstones the gallbladder is often also removed.[1] In chronic pancreatitis, in addition to the above, temporary feeding through a nasogastric tube may be used to provide adequate nutrition.[1] Long-term dietary changes and pancreatic enzyme replacement may be required.[1] Occasionally, surgery is done to remove parts of the pancreas.[1]
Globally, in 2015 about 8.9 million cases of pancreatitis occurred.[6] This resulted in 132,700 deaths, up from 83,000 deaths in 1990.[7][8] Acute pancreatitis occurs in about 30 per 100,000 people a year.[3] New cases of chronic pancreatitis develop in about 8 per 100,000 people a year and currently affect about 50 per 100,000 people in the United States.[9] It is more common in men than women.[1] Often chronic pancreatitis starts between the ages of 30 and 40 and is rare in children.[1] Acute pancreatitis was first described on autopsy in 1882 while chronic pancreatitis was first described in 1946.[9]
Late complications include recurrent pancreatitis and the development of pancreatic pseudocysts—collections of pancreatic secretions that have been walled off by scar tissue. These may cause pain, become infected, rupture and bleed, block the bile duct and cause jaundice, or migrate around the abdomen. Acute necrotizing pancreatitis can lead to a pancreatic abscess, a collection of pus caused by necrosis, liquefaction, and infection. This happens in approximately 3% of cases or almost 60% of cases involving more than two pseudocysts and gas in the pancreas.[11]
There are seven classes of medications associated with acute pancreatitis: statins, ACE inhibitors, oral contraceptives/hormone replacement therapy (HRT), diuretics, antiretroviral therapy, valproic acid, and oral hypoglycemic agents. Mechanisms of these drugs causing pancreatitis are not known exactly, but it is possible that statins have direct toxic effect on the pancreas or through the long-term accumulation of toxic metabolites. Meanwhile, ACE inhibitors cause angioedema of the pancreas through the accumulation of bradykinin. Birth control pills and HRT cause arterial thrombosis of the pancreas through the accumulation of fat (hypertriglyceridemia). Diuretics such as furosemide have a direct toxic effect on the pancreas. Meanwhile, thiazide diuretics cause hypertriglyceridemia and hypercalcemia, where the latter is the risk factor for pancreatic stones.[citation needed]
HIV infection itself can cause a person to be more likely to get pancreatitis. Meanwhile, antiretroviral drugs may cause metabolic disturbances such as hyperglycemia and hypercholesterolemia, which predisposes to pancreatitis. Valproic acid may have direct toxic effect on the pancreas.[20] Various oral hypoglycemic agents are associated with pancreatitis including metformin, but glucagon-like peptide-1 mimetics such as exenatide are more strongly associated with pancreatitis by promoting inflammation in combination with a high-fat diet.[21]
Characteristic acute onset of epigastric or vague abdominal pain that may radiate to the back (see signs and symptoms above)
Serum amylase or lipase levels ≥ 3 times the upper limit of normal
An imaging study with characteristic changes. CT, MRI, abdominal ultrasound or endoscopic ultrasound can be used for diagnosis.
Amylase and lipase are 2 enzymes produced by the pancreas. Elevations in lipase are generally considered a better indicator for pancreatitis as it has greater specificity and has a longer half life.[30] However, both enzymes can be elevated in other disease states. In chronic pancreatitis, the fecal pancreatic elastase-1 (FPE-1) test is a marker of exocrine pancreatic function. Additional tests that may be useful in evaluating chronic pancreatitis include hemoglobin A1C, immunoglobulin G4, rheumatoid factor, and anti-nuclear antibody.[31]
For imaging, abdominal ultrasound is convenient, simple, non-invasive, and inexpensive.[32] It is more sensitive and specific for pancreatitis from gallstones than other imaging modalities.[30] However, in 25–35% of patients the view of the pancreas can be obstructed by bowel gas making it difficult to evaluate.[29]
A contrast-enhanced CT scan is usually performed more than 48 hours after the onset of pain to evaluate for pancreatic necrosis and extrapancreatic fluid as well as predict the severity of the disease. CT scanning earlier can be falsely reassuring.[33]
ERCP or an endoscopic ultrasound can also be used if a biliary cause for pancreatitis is suspected.[citation needed]
Treatment
The treatment of pancreatitis is supportive and depends on severity. Morphine generally is suitable for pain control. There are no clinical studies to suggest that morphine can aggravate or cause pancreatitis or cholecystitis.[34]
The treatment for acute pancreatitis will depend on whether the diagnosis is for the mild form of the condition, which causes no complications, or the severe form, which can cause serious complications.[citation needed]
Mild acute pancreatitis
The treatment of mild acute pancreatitis is successfully carried out by admission to a general hospital ward. Traditionally, people were not allowed to eat until the inflammation resolved but more recent evidence suggests early feeding is safe and improves outcomes, and may result in an ability to leave the hospital sooner.[35]
Due to inflammation occurring in pancreatitis, proinflammatory cytokines secreted into the bloodstream can cause inflammation throughout the body, including the lungs and can manifest as ARDS. Because pancreatitis can cause lung injury and affect normal lung function, supplemental oxygen is occasionally delivered through breathing tubes that are connected via the nose (e.g., nasal cannulae) or via a mask. The tubes can then be removed after a few days once it is clear that the condition is improving.[citation needed]
Dehydration may result during an episode of acute pancreatitis, so fluids will be provided intravenously.[citation needed]
Opioids may be used for the pain. When the pancreatitis is due to gallstones, early gallbladder removal also appears to improve outcomes.[36]
Severe acute pancreatitis
Severe pancreatitis can cause organ failure, necrosis, infected necrosis, pseudocyst, and abscess. If diagnosed with severe acute pancreatitis, people will need to be admitted to a high-dependency unit or intensive care unit. It is likely that the levels of fluids inside the body will have dropped significantly as it diverts bodily fluids and nutrients in an attempt to repair the pancreas. The drop in fluid levels can lead to a reduction in the volume of blood within the body, which is known as hypovolemic shock. Hypovolemic shock can be life-threatening as it can very quickly starve the body of the oxygen-rich blood that it needs to survive. To avoid going into hypovolemic shock, fluids will be administered intravenously. Oxygen will be supplied through tubes attached to the nose and ventilation equipment may be used to assist with breathing. Feeding tubes may be used to provide nutrients, combined with appropriate analgesia.[citation needed]
As with mild pancreatitis, it will be necessary to treat the underlying cause—gallstones, discontinuing medications, cessation of alcohol, etc. If the cause is gallstones, it is likely that an ERCP procedure or removal of the gallbladder will be recommended. The gallbladder should be removed during the same hospital admission or within two weeks of pancreatitis onset so as to limit the risk of recurrent pancreatitis.[citation needed]
If the cause of pancreatitis is alcohol, cessation of alcohol consumption and treatment for alcohol dependency may improve pancreatitis. Even if the underlying cause is not related to alcohol consumption, doctors recommend avoiding it for at least six months as this can cause further damage to the pancreas during the recovery process.[37]
Oral intake, especially fats, is generally restricted initially but early enteral feeding within 48 hours has been shown to improve clinical outcomes.[38]Fluids and electrolytes are replaced intravenously. Nutritional support is initiated via tube feeding to surpass the portion of the digestive tract most affected by secreted pancreatic enzymes if there is no improvement in the first 72–96 hours of treatment.[39]
Prognosis
Severe acute pancreatitis has mortality rates around 2–9%, higher where necrosis of the pancreas has occurred.[40]
Several scoring systems are used to predict the severity of an attack of pancreatitis. They each combine demographic and laboratory data to estimate severity or probability of death. Examples include APACHE II, Ranson, BISAP, and Glasgow. The Modified Glasgow criteria suggests that a case be considered severe if at least three of the following are true:[41]
The BISAP score (blood urea nitrogen level >25 mg/dL (8.9 mmol/L), impaired mental status, systemic inflammatory response syndrome, age over 60 years, pleural effusion) has been validated as similar to other prognostic scoring systems.[42]
Epidemiology
Globally the incidence of acute pancreatitis is 5 to 35 cases per 100,000 people. The incidence of chronic pancreatitis is 4–8 per 100,000 with a prevalence of 26–42 cases per 100,000.[43] In 2013 pancreatitis resulted in 123,000 deaths up from 83,000 deaths in 1990.[8]
Costs
In adults in the United Kingdom, the estimated average total direct and indirect costs of chronic pancreatitis is roughly £79,000 per person on an annual basis.[44] Acute recurrent pancreatitis and chronic pancreatitis occur infrequently in children, but are associated with high healthcare costs due to substantial disease burden.[45] Globally, the estimated average total cost of treatment for children with these conditions is approximately $40,500/person/year.[45]
^NIDDK (July 2008). "Pancreatitis". National Digestive Diseases Information Clearinghouse. U.S. National Institute of Diabetes and Digestive and Kidney Diseases. 08–1596. Archived from the original on 2007-01-07. Retrieved 2007-01-05.
^"Pancreatitis". A.D.A.M., Inc. Archived from the original on 2012-12-30. Retrieved 2013-01-05.
^Jones MR, Hall OM, Kaye AM, Kaye AD (2015). "Drug-induced acute pancreatitis: a review". The Ochsner Journal. 15 (1): 45–51. PMC4365846. PMID25829880. Various oral hypoglycemic agents used in the treatment of diabetes are linked to acute pancreatitis. While some association exists between the occurrence of pancreatitis and biguanide agents such as metformin, as well as with dipeptidyl peptidase 4 inhibitors, including sitagliptin, vildagliptin, and saxagliptin, current research suggests that the only oral hypoglycemic agents with a disproportionately increased risk of pancreatitis are the glucagon-like peptide-1 (GLP-1) mimetics. Of particular concern is exenatide that was linked to 36 postmarketing reports of acute pancreatitis soon after its introduction. Further inquiry has estimated a 6-fold increase in the risk of pancreatitis with the use of exenatide compared to other therapies. The pathogenesis of GLP-1 analog-induced pancreatitis is unclear, but current evidence suggests an additive or synergistic exacerbation of pancreatitis when GLP-1 analogs are used in the presence of a high fat diet. The sequence of injury appears to begin with acinar cell hypertrophy, progress to proinflammatory cytokine induction, and culminate in pancreatic vascular injury
^ abHospitalist Handbook (4th ed.). Department of Medicine University of California, San Francisco. 2012. pp. 224–25.
^Greenberger NJ, Wu B, Conwell D, Banks P (eds.). "Chronic Pancreatitis". Gastroenterology, Hepatology, & Endoscopy. Current Medical Diagnosis and Treatment. p. 301.
^Vaughn VM, Shuster D, Rogers MA, Mann J, Conte ML, Saint S, Chopra V (June 2017). "Early Versus Delayed Feeding in Patients With Acute Pancreatitis: A Systematic Review". Annals of Internal Medicine. 166 (12): 883–892. doi:10.7326/M16-2533. PMID28505667. S2CID2025443.
^Moody N, Adiamah A, Yanni F, Gomez D (October 2019). "Meta-analysis of randomized clinical trials of early versus delayed cholecystectomy for mild gallstone pancreatitis". The British Journal of Surgery. 106 (11): 1442–1451. doi:10.1002/bjs.11221. PMID31268184. S2CID195787962.
^Corfield AP, Cooper MJ, Williamson RC, Mayer AD, McMahon MJ, Dickson AP, et al. (August 1985). "Prediction of severity in acute pancreatitis: prospective comparison of three prognostic indices". Lancet. 2 (8452): 403–7. doi:10.1016/S0140-6736(85)92733-3. PMID2863441. S2CID46327341.
^Papachristou GI, Muddana V, Yadav D, O'Connell M, Sanders MK, Slivka A, Whitcomb DC (February 2010). "Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis". The American Journal of Gastroenterology. 105 (2): 435–41, quiz 442. doi:10.1038/ajg.2009.622. PMID19861954. S2CID41655611.
^Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J (2015). "Chapter 370 Approach to the Patient with Pancreatic Disease". Harrison's Principles of Internal Medicine (19th ed.). McGraw Hill Professional. ISBN978-0071802161.
^Hall TC, Garcea G, Webb MA, Al-Leswas D, Metcalfe MS, Dennison AR (June 2014). "The socio-economic impact of chronic pancreatitis: a systematic review". Journal of Evaluation in Clinical Practice. 20 (3): 203–7. doi:10.1111/jep.12117. PMID24661411.